Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | 48.84% | -120.46% | -480.48% | 94.25% |
| Total Depreciation and Amortization | 0.00% | -4.74% | -7.94% | 9.57% | -14.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -100.75% | 1,023.96% | 105.66% | -166.06% |
| Change in Net Operating Assets | 0.00% | -88.05% | 521.72% | -188.76% | 197.90% |
| Cash from Operations | 0.00% | -17.00% | 12.78% | 15.77% | 4.62% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 0.00% | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -12.20% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | 421.21% | -99.73% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00% | 4,708.33% | 64.06% | -101.78% | 4,964.20% |
| Foreign Exchange rate Adjustments | 0.00% | 92.63% | -978.43% | -82.23% | 210.38% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.00% | 58.88% | 10.44% | -202.11% | 177.16% |